Good MorningU.S. stocks finished slightly lower Monday as uncertainty surrounding the Strait of Hormuz pushed energy prices higher. Brent crude rose nearly 5% to $87.50 a barrel, putting renewed focus on inflation risks and the impact of higher fuel costs on consumers and corporate margins.
Technology trading was mixed. NVIDIA reportedly lost about $130 billion in market value amid reports tied to a potential $500 billion AI infrastructure financing effort, while Intel fell after announcing plans to raise $15 billion through a common-stock sale. Investors also weighed reports that Microsoft is preparing to unveil its Maia 300 AI chip this fall as it expands its custom silicon efforts.
Berkshire Hathaway advanced after better-than-expected second-quarter earnings, while Hewlett Packard Enterprise rose following a Morgan Stanley upgrade. Investors also continued to parse earnings, with Monday.com falling despite a quarterly beat after its outlook disappointed. Featured: A Few Quiet Tickers Are Moving. (Stock News Trends Today) (Ad) 
|
Technology | |
SoundHound AI’s (NASDAQ: SOUN) market sent a clear signal following its Q2 earnings report, surging more than 30% on the news and closing the week at its highs. The move reveals solid support at long-term lows, a critical support target given the ultra-high short interest, and a high probability th... Read the Full Story |
|
From Our Partners | | Elon can't build his satellite network without one key supplier, and he's paid this company since 2012.
His plan for 1,000,000 satellites could multiply that bill significantly, putting this overlooked stock back in focus.
Dylan has circled December 8th as a key date for this pick. | | Claim today's free stock pick before December 8th |
|
Utilities | |
The S&P 500 finally made a new all-time high on Aug. 4, its first new record in more than two months. But while the index was notching its high, the volatility index (VIX) also spiked 4%, indicating a flurry of options activity under the market’s surface.
Inflation is still elevated, the war in... Read the Full Story |
|
Technology | |
In today’s stock market environment, investors' minds often go to one specific theme when thinking about the “most upgraded” stocks among analysts: data centers and AI. This certainly makes sense, given the overwhelming presence of this theme that seems to leave little air left in the room for othe... Read the Full Story |
|
From Our Partners | | 232 companies listed on U.S. exchanges this year, and 86 priced IPOs had raised over $251 billion by late July alone - more than five times 2025's full-year total. Yet most carry almost no analyst coverage.
We screened the entire class for average daily volume above 500,000 shares, market caps over $100 million, and at least 18 months of cash runway. Only seven names cleared every filter - four already trading, three still private. | | See the seven IPOs that passed every filter. |
|
Technology | |
First Solar (NASDAQ: FSLR) is proving it can turn the clean-energy buildout into real profit. What comes next is hard to predict.
The company has moved past being a thematic bet on solar power. It’s become a profitable manufacturer with hard numbers to back up the narrative. It has a deep contracte... Read the Full Story |
|
Consumer Discretionary | |
This earnings season has delivered a hard lesson: beating estimates is no longer enough. Several richly valued names posted strong quarters only to sell off sharply as the market picked apart guidance, bookings, or spending plans. That makes the stocks that beat and either held their gains or exten... Read the Full Story |
|
From Our Partners | | Palantir, Micron and SanDisk show how fast a stock can become the trade everyone suddenly wants. That's often when investors make their costliest mistake: arriving after the easy part of the move is gone.
A new premium eBook flags 7 stocks that may be worth knowing about before the broader crowd catches on. You don't need to buy any of them - just knowing what's quietly gaining attention can be useful. | | See the 7 stocks on the watchlist while it's still free |
|
Consumer Discretionary | |
Wingstop (NASDAQ: WING) is still growing even as its stock shrinks. That contradiction defines the company right now.
Wingstop built its reputation over the past decade on the simple promise of an asset-light, high-margin franchising machine that turns wings into one of the more reliable growth st... Read the Full Story |
|
Consumer Staples | |
In a market consumed by artificial intelligence, where investors chase the next big breakthrough with almost feverish enthusiasm, there's something quietly reassuring about a company that simply sells fizzy drinks.
Coca-Cola Co. (NYSE: KO) will never be described as exciting, and that's precisely ... Read the Full Story |
|
Consumer Staples | |
Monster Beverage Corp. (NASDAQ: MNST) gave investors a little dessert before dinner. The main course, a 2-for-1 stock split, will take place after the market closes on Aug. 10. But if investors were wondering if there was a reason beyond the split to own MNST stock, they got a refreshing answer.
In... Read the Full Story |
|
Industrials | |
The market gets many things wrong about Symbotic (NASDAQ: SYM), including the significance of its swelling backlog and the multiyear growth runway it presents. The timing and lumpiness of early results aside, the company is ramping capacity while leaning into backlog conversion, accelerating both i... Read the Full Story |
|
Markets | |
Creating reliable passive income through exchange-traded fund (ETF) investments doesn't necessarily mean one has to seek out only ultra-high dividend yields, which often come with similarly significant management fees. It's possible to find attractive income funds that combine strong yields, broad ... Read the Full Story |
|
Tuesday's Early Bird Stock Of The Day AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. | Should I Buy AbbVie Stock? ABBV Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of AbbVie was last updated on Wednesday, November 04, 2026 at 6:25 PM.
AbbVie Bull Case -
AbbVie recently secured global rights to Nxera Pharma's experimental oral IBD candidate, NXE0033744, in a deal worth up to $1.47 billion including upfront payments and milestones, which diversifies the company's growth pipeline beyond its current immunology and oncology franchises.
-
The company is investing more than £120 million to expand its Oxford R&D facility, signaling a long-term commitment to advancing research in immunology, neurology, and oncology, which supports future product innovation and market expansion.
-
AbbVie reported strong third-quarter earnings with EPS of $3.82, beating analyst estimates of $3.73, and revenue of $17.40 billion, which was also above the consensus of $17.32 billion, demonstrating robust operational performance and demand for its key products like Skyrizi and Rinvoq.
-
Wall Street sentiment has improved significantly, with multiple brokerages including Morgan Stanley and Piper Sandler raising their price targets, and the stock currently trading at $294.15, which is near its 52-week high of $298.74, reflecting strong investor confidence in the company's trajectory.
-
AbbVie recently increased its quarterly dividend to $1.82 per share, representing a 5.2% increase from the previous $1.73, which provides a growing income stream for investors and signals management's confidence in the company's cash flow generation.
AbbVie Bear Case -
AbbVie discontinued a Phase 2 solid-tumor drug program due to "limited benefit," which is a setback for its oncology pipeline and may raise concerns about the success rate of its other experimental cancer treatments.
-
The company's valuation may be stretched after its recent rally, with a P/E ratio of 50.63, which is high compared to many peers, potentially limiting further upside if growth expectations are not met in the coming quarters.
-
AbbVie's payout ratio is currently 119.10%, meaning the company is paying out more in dividends than it is earning in net income, which could be a concern for long-term sustainability of the dividend if earnings do not grow sufficiently.
-
Insider selling has been notable, with EVP Nicholas Donoghoe selling 32,710 shares in August 2026, representing a 30.53% decrease in his position, which some investors may interpret as a lack of confidence in the stock's near-term performance.
-
Short interest has been relatively high, with 15.58 million shares shorted as of October 2026, which is a significant portion of the float and could indicate that some investors are betting against the stock's future performance.
| | View Today's Stock Pick |
|
